FDA meeting is today, page-41

Building on Garfus' post (I hope), an increased dosage in the context of a lengthened trial time heightens the importance of any safety/toxicity studies.

As the above are almost established attention then turns to efficacy. The measuring of this against a base case, where the "bar" for observable positive effect is put by the FDA, is part of the solution. Enough of an improvement in a space where there is no current effective, targeted therapy? I'm optimistic, not hopeful (because that's not useful in investing).

OV

PS TA, hammer, cup, head, etc. now is of NO use. It's about results. Full stop.